62
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Association between serum interleukin-6 levels with the risk and clinical severity of primary open-angle glaucoma

ORCID Icon, , &
Pages 505-510 | Received 09 Jun 2021, Accepted 04 Oct 2021, Published online: 22 Oct 2021

References

  • Ulhaq ZS, Soraya GV. Aqueous humor interleukin-6 levels in primary open-angle glaucoma (POAG): a systematic review and meta-analysis. Arch Soc Esp Oftalmol. 2020;95(7):315–321.
  • Ulhaq ZS. Chemokine IL-8 level in aqueous humor of open-angle glaucoma: a meta-analysis. Arch Soc Esp Oftalmol. 2020;95(3):114–119.
  • Ulhaq ZS. Vitamin D and its receptor polymorphisms are associated with glaucoma. Journal Français d’Ophtalmologie. 2020;43(10):1009–1019.
  • Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720.
  • Micera A, Quaranta L, Esposito G, et al. Differential protein expression profiles in glaucomatous trabecular meshwork: an evaluation study on a small primary open angle glaucoma population. Adv Ther. 2016;33(2):252–267.
  • Huang P, Qi Y, Xu Y-S, et al. Serum cytokine alteration is associated with optic neuropathy in human primary open angle glaucoma. J Glaucoma. 2010;19(5):324–330.
  • Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020;50(4):382–383.
  • Ulhaq ZS, Soraya GV, Budu, et al. The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis. Sci Rep. 2020;10:17453.
  • Lin K-H, Feng S-C, Shen Y-C, et al. Interleukin-6(−174) locus polymorphism and serum IL-6 levels in normal tension glaucoma. Ophthalmic Genet. 2014;35(4):255–257.
  • Inoue-Mochita M, Inoue T, Kojima S, et al. Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells. J Biol Chem. 2018;293(28):10975–10984.
  • Chidlow G, Wood JPM, Ebneter A, et al. Interleukin-6 is an efficacious marker of axonal transport disruption during experimental glaucoma and stimulates neuritogenesis in cultured retinal ganglion cells. Neurobiol Dis. 2012;48(3):568–581.
  • Niu J. Relation of serum and aqueous humor TNF-α and IL-6 with the process of neovascular glaucoma. Int Eye Sci. 2018;18:1684–1686.
  • Ghanem A, Arafa L, Elewa A. Tumor necrosis factor-α and interleukin-6 levels in patients with primary open-angle glaucoma. J Clin Exp Ophthalmol. 2011: 02.
  • Slepova OS, Arapiev MU, Lovpache DN, et al. Specifics of local and systemic cytokine profile in healthy people of different ages and patients with early stage of primary open-angle glaucoma [Internet]. National J Glaucoma. 2016 [cited 2021 Feb 2]. p. 3–12. Available from: https://www.glaucomajournal.ru/jour/article/view/90.
  • Aimaier A, Abula K. IL-6, IL-8 and TNF-a expression levels in serum and aqueous humor in patients with neovascular glaucoma and their significance. Int Eye Sci. 2018;18:1393–1396.
  • Ulhaq ZS. Comment on the assessment of “Association of interleukin-6 gene polymorphisms and glaucoma: systematic review and meta-analysis.” Eur J Ophthalmol. 2020;1120672120962049.
  • Soraya GV, Ulhaq ZS. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis. Medicina Clínica. 2020;155(4):143–151.
  • Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020;61(3):253–254.
  • Ulhaq ZS, Soraya GV. Roles of IL-8-251A/T and +781C/T polymorphisms, IL-8 level, and the risk of age-related macular degeneration. Arch Soc Esp Oftalmol. 2021 1 Sep;96(9):476-487.
  • Ulhaq ZS. The association of estrogen-signaling pathways and susceptibility to open-angle glaucoma. Beni-Suef Univ J Basic Appl Sci. 2020;9(1):7.
  • Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the Gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49(5):1–15.
  • Suurmond R, Van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Res Synth Methods. 2017;8(4):537–553.
  • Yanhong H, Hongping C. Levels of aqueous and serum VEGF, TGF-β1,IL-6 in neovascular glaucoma eyes. Chin J Exp Ophthalmol. 2016;34:624–629.
  • Zhen C, Li-hong S, Wei-xing W. Expression of serum inflammatory factors in patients with glaucoma at different stages and its clinical significance. Int Eye Sci. 2017;17:1894–1897.
  • Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(jul22 1):d4002.
  • Vidal-Sanz M, Salinas-Navarro M, Nadal-Nicolás FM, et al. Understanding glaucomatous damage: anatomical and functional data from ocular hypertensive rodent retinas. Prog Retin Eye Res. 2012;31(1):1–27.
  • Williams PA, Marsh-Armstrong N, Howell GR. Neuroinflammation in glaucoma: a new opportunity. Exp Eye Res. 2017;157:20–27.
  • Barış M, Tezel G. Immunomodulation as a neuroprotective strategy for glaucoma treatment. Curr Ophthalmol Rep. 2019;7(2):160–169.
  • Takai Y, Tanito M, Ohira A. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis Sci. 2012;53(1):241–247.
  • Kondkar AA, Sultan T, Almobarak FA, et al. Association of increased levels of plasma tumor necrosis factor alpha with primary open-angle glaucoma. Clin Ophthalmol. 2018;12:701–706.
  • Soto I, Howell GR. The complex role of neuroinflammation in glaucoma. Cold Spring Harb Perspect Med Internet]. 2014 [cited 2021 Feb 25];4. Available from. ; . : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109578/
  • Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013;13(1):23–31.
  • Freedman J, Iserovich P. Pro-inflammatory cytokines in glaucomatous aqueous and encysted molteno implant blebs and their relationship to pressure. Invest Ophthalmol Vis Sci. 2013;54(7):4851–4855.
  • Zhou G, Liu B. Single nucleotide polymorphisms of metabolic syndrome-related genes in primary open angle glaucoma. Int J Ophthalmol. 2010;3:36–42.
  • Jiang CQ, Lam TH, Liu B, et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity (Silver Spring). 2010;18(10):1969–1974.
  • Echevarria FD, Formichella CR, Sappington RM. Interleukin-6 deficiency attenuates retinal ganglion cell axonopathy and glaucoma-related vision loss. Front Neurosci Internet]. 2017 [cited 2021 Feb 25];11. Available from. ; . : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450377/
  • Shanmugam A, Wang J, Markand S, et al. Sigma Receptor 1 activation attenuates release of inflammatory cytokines MIP1γ, MIP2, MIP3α and IL12 (p40/p70) by retinal Müller glial cells. J Neurochem. 2015;132(5):546–558.
  • Almási N, Török S, Dvorácskó S, et al. Lessons on the Sigma-1 receptor in TNBS-induced rat colitis: modulation of the UCHL-1, IL-6 pathway. Int J Mol Sci. 2020;21(11):E4046.
  • Bucolo C, Campana G, Di Toro R, et al. Sigma1 recognition sites in rabbit iris-ciliary body: topical sigma1-site agonists lower intraocular pressure. J Pharmacol Exp Ther. 1999;289:1362–1369.
  • Platania CBM, Di Paola L, Leggio GM, et al. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol. 2015;6:248.
  • Song Y, Song Q, Li L, et al. Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage. Exp Ther Med. 2018;16:2506–2510.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.